Pascale Khairallah, Jenna Cherasard, Joshua Sung, Sanchita Agarwal, Maria Alejandra Aponte, Mariana Bucovsky, Maria Fusaro, Jeffrey Silberzweig, Gail N Frumkin, Karim El Hachem, Linda Schulman, Donald McMahon, Matthew R Allen, Corinne E Metzger, Rachel K Surowiec, Joseph Wallace, Thomas L Nickolas
INTRODUCTION: Secondary hyperparathyroidism is associated with osteoporosis and fractures. Etelcalcetide is an intravenous calcimimetic for the control of hyperparathyroidism in patients on hemodialysis. Effects of etelcalcetide on the skeleton are unknown. METHODS: In a single-arm, open-label, 36-week prospective trial, we hypothesized that etelcalcetide improves bone quality and strength without damaging bone-tissue quality. Participants were 18 years or older, on hemodialysis ≥1 year, without calcimimetic exposure within 12 weeks of enrollment...
August 14, 2023: Clinical Journal of the American Society of Nephrology: CJASN